The original thesis document lacks a list of figures and a list of tables. Those are provided below as erratum to thesis document.

**List of Figures**

Figure 1: Modelling and simulation during drug development [1] ........................................................................ 2

Figure 2: Two-compartment model. K12, K21 and K10 are first-order rate constants: K12 = rate of transfer from central to peripheral compartment; K21 = rate of transfer from peripheral to central compartment; ka = rate of absorption and k10 = rate of elimination from central compartment. ................................................... 4

Table 1: Advantages and Disadvantages of population pharmacokinetics modelling........................................... 6

Figure 3 : Cost effectiveness plane........................................................................................................................ 21

Table 2 : Parameter estimates for the final Glecaprevir model [71]. IIV = inter-individual variability, SEE = Standard Error of Estimate, % RSE = (Relative Standard Error), ........................................................................... 25

%RSE = SEEPopulation estimate*100 .................................................................................................................. 25

Table 3: Parameter estimates for the final Pibrentasvir model [71]. IIV = inter-individual variability, SEE = Standard Error of Estimate, % RSE = (Relative Standard Error), ........................................................................... 26

%RSE = SEEPopulation estimate*100 .................................................................................................................. 26

Table 4: Average ages of Phase 2 clinical studies made in FDA submission report for Mavyret® [71], accessed in clinical trial website [74]. ...................................................................................................................................... 29

Table 5: Average ages of Phase 3 clinical studies made in FDA submission report for Mavyret® [71], accessed in clinical trial website [74]. ...................................................................................................................................... 30

Figure 4: Average of plasma concentrations vs time plot for two drug products (Test and Reference) after oral administration. (Attachment 3) ............................................................................................................................ 33

Figure 5: Average of log of concentrations vs time plot for two drug products (Test and Reference) after oral administration. (Attachment 3) ............................................................................................................................ 33

Figure 6: Concentration-time graph plotted in Shiny application after intravenous administration with the addition of Differential equations. (Attachment 5) ............................................................................................................................ 33

Figure 7: Concentration-time graph plotted in Shiny application after intravenous administration with the addition of ETA (random effects in the model). (Attachment 6) ............................................................................................................................ 34

Figure 8: Simple concentration-time graph in Shiny with the calculation of their confidence interval (Attachment 7) ...................................................................................................................................................... 34

Figure 9: Concentration-time plot of a model in Shiny where slide bars are added to observe the change in graph simultaneously (Attachment 8) ...................................................................................................................................................... 35

Figure 10: Slide bars in the model created to observe the change in plot upon moving the sliders from one value to another (Attachment 8) ...................................................................................................................................................... 35

Figure 11: Model created with two compartmental model where concentrations in both compartments are plotted with the confidence interval of the concentration in central compartment ........................................................................... 36

Figure 12: This figure shows the screenshoot of the resultant display of user interface used in the building model of Glecaprevir in Shiny (Attachment 11) ...................................................................................................................................................... 37

Figure 13: This figure shows the screenshoot of the resultant display of user interface used in the building model of Pibrentasvir in Shiny (Attachment 12) ...................................................................................................................................................... 37

Figure 14: This figure shows the screenshoot of the resultant display of user interface used in the building model of Glecaprevir and Pibrentasvir in Shiny (Attachment 13) ...................................................................................................................................................... 38
Table 6: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both drugs (Glecaprevir and Pibrentasvir) when no covariate is used in the model ......................................................................................................... 38

Figure 15: The graph in this figure shows the mean concentrations of Pibrentasvir in red and Glecaprevir in blue in central compartment without using any covariate in the subjects .......................................................................................................................... 38

Figure 16: The plot in this figure shows the mean concentration of Pibrentasvir in central compartment without using any covariate in the subjects .......................................................................................................................... 39

Figure 17: The graph in this figure shows the mean concentration of Glecaprevir only in central compartment without using any covariate in the subjects .................................................................................................................. 39

Figure 18: The graph in this figure shows the mean concentrations of Pibrentasvir in central compartment with the interval of 85-87 days and without using any covariate in the subjects .......................................................................................................................... 39

Figure 19: The graph in this figure shows the mean concentrations of Glecaprevir in central compartment with the interval of 85-87 days and without using any covariate in the subjects .......................................................................................................................... 40

Figure 20: The graph in this figure shows the mean concentrations of Pibrentasvir in red and Glecaprevir in blue in central compartment with the group of patients that are suffering with mild renal impairment .......................................................................................................................... 40

Figure 21: The graph in this figure shows the mean concentrations of Pibrentasvir in central compartment with the group of patients that are suffering with mild renal impairment .......................................................................................................................... 40

Figure 22: The graph in this figure shows the mean concentrations of Glecaprevir in central compartment with the group of patients that are suffering with mild renal impairment .......................................................................................................................... 41

Figure 23: The graph in this figure shows the mean concentration of Pibrentasvir in central compartment with the interval of 85-87 days and with the group of patients that are suffering with mild renal impairment .......................................................................................................................... 41

Figure 24: The graph in this figure shows the mean concentration of Glecaprevir in central compartment with the interval of 85-87 days and with the group of patients that are suffering with mild renal impairment .......................................................................................................................... 41

Table 7: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both drugs (Glecaprevir and Pibrentasvir) when a model with a patients of mild renal impairment is used .......................................................................................................................... 41

Figure 25: The graph in this figure shows the mean concentrations of Pibrentasvir in red and Glecaprevir in blue in central compartment with the group of patients that are suffering with mild renal impairment and Cirrhosis .......................................................................................................................................................................................... 42

Figure 26: The graph in this figure shows the mean concentrations of Pibrentasvir in central compartment with the group of patients that are suffering with mild renal impairment and Cirrhosis .......................................................................................................................................................................................... 42

Figure 27: The graph in this figure shows the mean concentrations of Glecaprevir in central compartment with the group of patients that are suffering with mild renal impairment and Cirrhosis .......................................................................................................................................................................................... 42

Figure 28: The graph in this figure shows the mean concentration of Pibrentasvir in central compartment with the interval of 85-87 days and with the group of patients that are suffering with mild renal impairment and Cirrhosis .......................................................................................................................................................................................... 42

Figure 29: The graph in this figure shows the mean concentration of Glecaprevir in central compartment with the interval of 85-87 days and with the group of patients that are suffering with mild renal impairment and Cirrhosis .......................................................................................................................................................................................... 43

Table 8: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both drugs (Glecaprevir and Pibrentasvir) when a model with a patients of mild renal impairment and cirrhosis is used .......................................................................................................................................................................................... 43

Figure 30: The graph in this figure shows the mean concentrations of Pibrentasvir in red and Glecaprevir in blue in central compartment with the group of patients that are suffering with moderate + severe renal impairment .......................................................................................................................................................................................... 43

Figure 31: The graph in this figure shows the mean concentrations of Pibrentasvir in central compartment with the group of patients that are suffering with moderate + severe renal impairment .......................................................................................................................................................................................... 43

Figure 32: The graph in this figure shows the mean concentrations of Glecaprevir in central compartment with the group of patients that are suffering with moderate + severe renal impairment .......................................................................................................................................................................................... 44
Figure 33: The graph in this figure shows the mean concentration of Pibrentasvir in central compartment with the interval of 85-87 days and with the group of patients that are suffering with moderate + severe renal impairment ................................................................. 44

Figure 34: The graph in this figure shows the mean concentration of Glecaprevir in central compartment with the interval of 85-87 days and with the group of patients that are suffering with moderate + severe renal impairment ........................................................................................................ 44

Table 9: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both drugs (Glecaprevir and Pibrentasvir) when a model with patients of moderate + severe renal impairment is used ...................... 44

Figure 35: The graph in this figure shows the mean concentrations of Pibrentasvir in red and Glecaprevir in blue in central compartment with the group of patients that are suffering with moderate + severe renal impairment and cirrhosis .............................................................................. 45

Figure 36: The graph in this figure shows the mean concentrations of Pibrentasvir in central compartment with the group of patients that are suffering with moderate + severe renal impairment and cirrhosis .............................................................................. 45

Figure 37: The graph in this figure shows the mean concentrations of Glecaprevir in central compartment with the group of patients that are suffering with moderate + severe renal impairment and cirrhosis .............................................................................. 45

Figure 38: The graph in this figure shows the mean concentration of Pibrentasvir in central compartment with the interval of 85-87 days and with the group of patients that are suffering with moderate + severe renal impairment and cirrhosis .............................................................................. 45

Figure 39: The graph in this figure shows the mean concentration of Glecaprevir in central compartment with the interval of 85-87 days and with the group of patients that are suffering with moderate + severe renal impairment and cirrhosis .............................................................................. 45

Table 10: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both drugs (Glecaprevir and Pibrentasvir) when a model with a patients of mild renal impairment and cirrhosis is used ... 46

Figure 40: The plot in this figure shows the mean concentrations of Pibrentasvir in red and Glecaprevir in blue in central compartment with the group of patients that are suffering with end stage impairment .............................................................................. 46

Figure 41: The graph in this figure shows the mean concentrations of Pibrentasvir in central compartment with the group of patients that are suffering with end stage impairment .............................................................................. 46

Figure 42: The graph in this figure shows the mean concentrations of Glecaprevir in central compartment with the group of patients that are suffering with end stage impairment .............................................................................. 47

Figure 43: The plot in this figure shows the mean concentration of Pibrentasvir in central compartment with the interval of 85-87 days and with the group of patients that are suffering with end stage impairment .............................................................................. 47

Figure 44: The graph in this figure shows the mean concentration of Glecaprevir in central compartment with the interval of 85-87 days and with the group of patients that are suffering with end stage impairment .............................................................................. 47

Table 11: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both drugs (Glecaprevir and Pibrentasvir) when a model with patients end stage impairment is used .............................................................................. 47

Figure 45: The graph in this figure shows the mean concentrations of Pibrentasvir in red and Glecaprevir in blue in central compartment in the group of patients that are suffering with end stage impairment and cirrhosis .............................................................................. 48

Figure 46: The graph in this figure shows the mean concentrations of Pibrentasvir in central compartment in the group of patients that are suffering with end stage impairment and cirrhosis .............................................................................. 48

Figure 47: The graph in this figure shows the mean concentrations of Glecaprevir in central compartment in the group of patients that are suffering with end stage impairment and cirrhosis .............................................................................. 48

Figure 48: The plot in this figure shows the mean concentration of Pibrentasvir in central compartment with the interval of 85-87 days and in the group of patients that are suffering with end stage impairment and cirrhosis .............................................................................. 48

Figure 49: The graph in this figure shows the mean concentration of Glecaprevir in central compartment with the interval of 85-87 days and with the group of patients that are suffering with end stage impairment and cirrhosis .............................................................................. 49